Topical Anti-TNFα Agent Licaminlimab (OCS-02) Relieves Persistent Ocular Discomfort in Severe Dry Eye Disease: A Randomized Phase II Study

Overview of attention for article published in Clinical Ophthalmology, July 2022

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (94th percentile)
High Attention Score compared to outputs of the same age and source (93rd percentile)

So far, Altmetric has seen 5 news stories from 5 outlets.

ACN Newswire 2022-08-23 LAUSANNE, Switzerland, Aug 23, 2022 - (ACN Newswire) - Oculis S.A., ('Oculis') a global ophthalmology…

- (ACN Newswire) - Oculis S.A., ('Oculis') a global ophthalmology company developing life-changing treatments to save sight and…

- Clinical Ophthalmology期刊發表的II期數據積極正面，突顯出利卡明利單抗（licaminlimab）有潛力成為乾眼病的新療法 - 成功達到主要和次要療效指標，顯示利卡明利單抗在緩解嚴重干眼病患者眼部不適方面優於賦形劑 - 利卡明利單抗…

Positive Phase 2 data, published in Clinical Ophthalmology, highlights the potential of licaminlimab to become a novel…

Positive Phase 2 data, published in Clinical Ophthalmology, highlights the potential of licaminlimab to become a novel…